4070 super game
Originally published Dec. 13 on IdahoCapitalSun.com . Officials are still not close to reaching their goal of returning at least 5 million salmon and steelhead to the Columbia River Basin. However, new data shows a positive trend in total abundance of fish in the basin. That’s according to the Northwest Power and Conservation Council , which on Tuesday met over Zoom to discuss the latest data of salmon and steelhead populations in the Columbia River Basin. Before 1850, salmon and steelhead runs to the Columbia River Basin were estimated to have been between 10 to 16 million annually. Dams significantly fractured those runs, and in the 1990s, runs declined to about 1 million a year. However, the most recent 10-year rolling average from 2014-2023 stands at 2.3 million salmon and steelhead returning to the basin, similar to the average of 2.4 million fish between 2004-2013, and an improvement from the average in the 1990s which fell to 1.3 million fish, according to data from the council. “Increased salmon and steelhead abundance in the Columbia River Basin — especially above Bonneville Dam — over the past 40 years marks important progress,” Councilmember Louie Pitt, who represents Oregon and is a member of the Confederated Tribes of the Warm Springs, said in a press release. The Northwest Power and Conservation Council was established in 1980 by the Northwest Power Act , which authorized Idaho, Montana, Oregon and Washington to develop a program to protect, mitigate and enhance fish and wildlife impacted by hydropower systems in the Columbia River Basin. The council’s fish and wildlife program is funded by the Bonneville Power Administration, and it directs more than $280 million annually to cover 300 projects throughout the basin. In 1987, the council set a goal to have 5 million salmon and steelhead return to the basin past Bonneville Dam by 2025. And through the 1990s, 12 salmon and steelhead populations in the Columbia River Basin were listed for protection under the Endangered Species Act as run sizes continued to decline. Since then, the closest the council has been to reaching its 5 million goal was in 2014, when 4.6 million salmon and steelhead returned to the basin. While dams are a primary hindrance to salmon and steelhead population recovery, these fish also face severe stresses from climate change, pressures from human population growth in the basin, and other environmental impacts, Pitt said. “We cannot ease up in our collective efforts to help these fish populations grow stronger and larger everywhere we can — including in blocked areas of our basin such as above Chief Joseph and Grand Coulee dams,” Pitt said. Ed Schriever, a council member who represents Idaho and is a former director of the Idaho Department of Fish and Game, said the progress is a result of the coordination between state, federal and tribal agencies and other partners across the Columbia River Basin. “Over the past four decades the region’s fish and wildlife managers have significantly increased their capacity to perform mitigation, stewardship, and enhancement,” Schriever said in the press release. “The managers have also refined their methods and processes as our scientific understanding has evolved and grown more sophisticated. The work being done today is more directed and purposeful than it has ever been.” Another key finding from Tuesday’s presentation is an improvement in salmon and steelhead production above Bonneville Dam since the establishment of the council Endangered Species Act listings. Early initiatives of the 20th century to recover salmon and steelhead populations, such as hatcheries, focused mostly in the lower sections of the Columbia River to benefit commercial fisheries and ocean harvest, said Peter Jensen, council spokesperson. This ignored fisheries upstream, particularly those for tribes, which experienced the heaviest losses of salmon and steelhead abundance. Since then, new hatcheries upstream of Bonneville Dam, many managed or co-managed by tribes, have helped offset some of those losses. The data presented on Tuesday gives a more complete picture of salmon and steelhead returns in the basin, showing current and historical estimates of proportions of ocean harvest, returns to the mouth of the river, and adult fish tracked passing Bonneville Dam as they migrate upriver to spawn. Previous efforts only focused on fish migrating past Bonneville Dam.KUALA LUMPUR, Malaysia, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”) (Nasdaq:GTI), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, today announced that management will host a webcast and conference call to provide a business update at 9 AM ET on Thursday, December 12, 2024. A live webcast of the call will be available by clicking here . Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may also access the call by dialing (877) 407-9208 for domestic callers or (201) 493-6784 for international callers. A replay of the call will be available for two weeks by dialing (844) 512-2921 for domestic callers or (412) 317-6671 for international callers and using Conference ID: 13750405. The archived webcast will be available in the Investor Relations section of the Company’s website. About Graphjet Technology Sdn. Bhd. Graphjet Technology Sdn. Bhd. (Nasdaq: GTI) was founded in 2019 in Malaysia as an innovative graphene and graphite producer. Graphjet Technology has the world’s first patented technology to recycle palm kernel shells generated in the production of palm seed oil to produce single layer graphene and artificial graphite. Graphjet’s sustainable production methods utilizing palm kernel shells, a waste agricultural product that is common in Malaysia, will set a new shift in graphite and graphene supply chain of the world. For more information, please visit https://www.graphjettech.com/ . Graphjet Technology Contacts Investors GraphjetIR@icrinc.com Media GraphjetPR@icrinc.com
Jimmy Carter: Many Evolutions For A Centenarian ‘Citizen Of The World’
Massive change to pension rules planned in savings boost for millions – but experts warn about risk to savers
Missouri Republican lawmaker wants to require schools to display the Ten CommandmentsGiants topple Colts 45-33 to eliminate Indy from the playoff raceThe Shale Giant Showdown: 2 Oil Stocks to Watch in 2025
MELBOURNE, Australia and INDIANAPOLIS , Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], 89 Zr- girentuximab) kidney cancer imaging[2]. TLX250-CDx is an investigational PET[3] drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix's successful urology imaging franchise. The FDA is expected to advise the PDUFA[4] goal date following the 60-day administrative review of the application. Kevin Richardson , Chief Executive Officer, Precision Medicine at Telix, stated, "We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC." About TLX250-CDx TLX250-CDx (Zircaix® 1 ) is an investigational PET agent that is under development for the diagnosis and characterisation of ccRCC. Telix's pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118 ) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterising ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA) [7], and by Health Canada [8] . No other Telix product has received a marketing authorisation in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn . Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States . The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix® and Zircaix® 1 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
Tulane QB Mensah transfers to Duke
Legal and political dynamics intensified as President-elect Donald Trump secured a delay in his New York sentencing on felony counts of falsifying business records, while his legal team pushes for dismissal under presidential immunity protections. The case, stemming from payments tied to adult film actress Stormy Daniels during the 2016 election, now faces fresh questions amid Trump's imminent return to the presidency. What Happened: State Judge Juan Merchan granted Trump's request to postpone sentencing to consider arguments about immunity, NBC News reports . Trump's attorneys assert that the recent Supreme Court decision on presidential protections applies to his conviction, seeking to have the case dismissed entirely. Proceedings have been rescheduled, with defense filings due by Dec. 2 and responses from prosecutors by Dec. 9. Prosecutors acknowledged Trump's status as president-elect presents unprecedented legal questions. According to NBC News, they suggested sentencing could be deferred until the end of his term, citing the need to balance constitutional interests. Also Read: Nate Silver Says Biden Should Resign, Have Harris Take Over Presidency: ‘It’s A Very Difficult Job’ Why It Matters: The delay underscores the broader implications of presidential immunity, a contentious issue reshaped by recent Supreme Court rulings. As Trump prepares to take office in January, his legal battles highlight the tension between political power and judicial accountability. Separately, Trump announced the nomination of Pam Bondi as attorney general, replacing Matt Gaetz , who withdrew amid ethics concerns. Bondi, Florida's former attorney genera l and a key figure in Trump's 2020 impeachment defense, is expected to refocus the Department of Justice (DOJ) under the new administration. Trump described the DOJ as "weaponized" and pledged to redirect its priorities. Read Next: Kennedy’s War On Food Dyes Could Be Coming To Your Breakfast Table Image created using artificial intelligence via Midjourney. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.The AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . ALBANY, N.Y. (AP) — Justin Neely’s 16 points off the bench led Albany (NY) to a 77-70 victory against Stony Brook on Sunday. Neely also contributed nine rebounds for the Great Danes (8-7). Amar’e Marshall scored 15 points, going 6 of 9 (3 for 6 from 3-point range). Kacper Klaczek had 10 points and shot 4 for 8 (0 for 3 from 3-point range) and 2 of 3 from the free-throw line. Ben Wight led the way for the Seawolves (4-9) with 19 points and seven rebounds. Joseph Octave added 13 points and five steals for Stony Brook. Jared Frey finished with 13 points. Albany (NY) took the lead with 19:30 left in the first half and did not give it up. Marshall led their team in scoring with 10 points in the first half to help put them ahead 36-31 at the break. Albany (NY) used an 8-0 run in the second half to build a 19-point lead at 55-36 with 14:01 left in the half before finishing off the win. Albany (NY) plays Saturday against UMass-Lowell at home, and Stony Brook visits Monmouth on Thursday. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .